Abstract
Tyrosine kinase inhibitors show great promise as clinical therapies, but small molecule inhibitors that are available in the clinic and under development bind to the adenosine triphosphate binding domain of the kinase, potentially limiting efficacy and selectivity. The development of antisense peptide inhibitors is a relatively unexplored area of research, and here we investigate inhibitory peptides specific for the Janus-associated kinase (JAK) family member, tyrosine kinase 2 (TYK2). We have developed peptides that are 2–3 times more selective for TYK2 than other JAK family members, with a TYK2 IC50 of 1.2 μM. In addition, TYK2 inhibitory peptides show specificity for TYK2-mediated functions over JAK1 functions in cell-based assays. These peptides provide a new tool for the development of specific peptide inhibitors for closely related tyrosine kinases.
Keywords: Antisense peptide, JAK, TYK2, tyrosine kinase.
Protein & Peptide Letters
Title:Design of a Peptide Inhibitor of Tyrosine Kinase 2
Volume: 21 Issue: 5
Author(s): Melissa G. Works, Benben Song, Patrick Kibler, Mary J. Tanga, Amit K. Galande and Annalisa D’Andrea
Affiliation:
Keywords: Antisense peptide, JAK, TYK2, tyrosine kinase.
Abstract: Tyrosine kinase inhibitors show great promise as clinical therapies, but small molecule inhibitors that are available in the clinic and under development bind to the adenosine triphosphate binding domain of the kinase, potentially limiting efficacy and selectivity. The development of antisense peptide inhibitors is a relatively unexplored area of research, and here we investigate inhibitory peptides specific for the Janus-associated kinase (JAK) family member, tyrosine kinase 2 (TYK2). We have developed peptides that are 2–3 times more selective for TYK2 than other JAK family members, with a TYK2 IC50 of 1.2 μM. In addition, TYK2 inhibitory peptides show specificity for TYK2-mediated functions over JAK1 functions in cell-based assays. These peptides provide a new tool for the development of specific peptide inhibitors for closely related tyrosine kinases.
Export Options
About this article
Cite this article as:
Works G. Melissa, Song Benben, Kibler Patrick, Tanga J. Mary, Galande K. Amit and D’Andrea Annalisa, Design of a Peptide Inhibitor of Tyrosine Kinase 2, Protein & Peptide Letters 2014; 21 (5) . https://dx.doi.org/10.2174/0929866520666131203101841
DOI https://dx.doi.org/10.2174/0929866520666131203101841 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Combinations Against Combinations: Associations of Anti-HIV 1 Reverse Transcriptase Drugs Challenged by Constellations of Drug Resistance Mutations
Current Drug Metabolism Translating Genetic Findings into Therapy in Parkinson Disease
Recent Patents on CNS Drug Discovery (Discontinued) Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem
Current Drug Targets Current Non-viral Gene Therapy Strategies for the Treatment of Glioblastoma
Current Medicinal Chemistry Immune Therapy of Multiple Sclerosis - Future Strategies
Current Pharmaceutical Design Profiling Drug Membrane Transport via Immobilized Artificial Membrane Chromatography
Current Pharmaceutical Analysis The Cytoskeleton as a Therapeutic Target in Childhood Acute Leukemia:Obstacles and Opportunities
Current Drug Targets L-Cysteine Catalyzed Environmentally Benign One-pot Multicomponent Approach Towards the Synthesis of Dihydropyrano[2,3-c]pyrazole Derivatives
Current Organic Synthesis Diagnosis, Pathogenesis and Therapeutic Targets in Amyotrophic Lateral Sclerosis
CNS & Neurological Disorders - Drug Targets Angiotensin II Type 1 Receptor Antagonist as an Angiogenic Inhibitor in Urogenital Cancer
Reviews on Recent Clinical Trials Novel Strategies to Target Inflammatory Processes in Atherosclerosis
Current Pharmaceutical Design Rutin-Phospholipid Complex: An Innovative Technique in Novel Drug Delivery System- NDDS
Current Drug Delivery Exhaled Breath Biomarkers in Asthmatic Children
Inflammation & Allergy - Drug Targets (Discontinued) Melanoma
Current Cancer Therapy Reviews Anti-Inflammatory Effects of Fibrates: An Overview
Current Medicinal Chemistry Androgen Receptor Cofactors in Prostate Cancer: Potential Therapeutic Targets of Castration-Resistant Prostate Cancer
Current Cancer Drug Targets Vitamin D/VDR in Acute Kidney Injury: A Potential Therapeutic Target
Current Medicinal Chemistry Role of Cytokines in Neurological Disorders
Current Medicinal Chemistry Kv7 Channels as Targets for the Treatment of Pain
Current Pharmaceutical Design Castration-resistant Prostate Cancer: The Targeting of Bone Microenvironment-related Survival Factors For Prostate Cancer Cells
Clinical Cancer Drugs